InĂªs Martins, PhD,  managing science editor—

InĂªs holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, InĂªs won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by InĂªs Martins

Gene Therapy Improves PAH Symptoms in Animal Models

Gene therapy may offer a promising therapeutic approach for pulmonary arterial hypertension (PAH), according to an animal study conducted by Japanese researchers. The study “Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension,” published in Molecular Therapy Methods and Clinical Development, shows…

Echocardiography May Be Easier Way to Predict Outcomes in PAH Patients

Measuring right ventricular (RV) function in patients with pulmonary arterial hypertension (PAH) using echocardiography is useful to predict patients’ prognosis, according to researchers at the Fondazione IRCCS Policlinico San Matteo in Italy. This may be of clinical relevance because echocardiography is cheaper and provides faster results than standard techniques, such as cardiac magnetic resonance…

EMA Halts Use of Adempas (Riociguat) for PH Associated Idiopathic Interstitial Pneumonia

The European Medicines Agency (EMA), the European Union parallel to the U.S. Food and Drug Administration (FDA), advised that the therapy Adempas (riociguat) should not be prescribed to patients with PH associated with idiopathic interstitial pneumonia (PH-IIP). According to a press release, EMA’s recommendation was supported by results of a Phase 2…

Bosentan Improved Endothelial Function in PAH, but Not in CTEPH Patients, Study Finds

Researchers at the Nagoya University Graduate School of Medicine in Japan demonstrated that the endothelin receptor antagonist bosentan can improve endothelial dysfunction parameters in patients with pulmonary arterial hypertension (PAH), but not in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). The findings were published in the Pulmonary…

PAH Patient Survival may be Predicted by Plasma Levels of Two Lipid Metabolites

Researchers from Tufts Medical Center in Boston identified two new biomarkers that may help predict survival in patients with pulmonary arterial hypertension (PAH). Findings from the study “Plasma 12- and 15-hydroxyeicosanoids are predictors of survival in pulmonary arterial hypertension,” were recently published in the journal Pulmonary Circulation. PAH…